HGF/c-Met signaling is a well-established oncogenic pathway: c-Met is amplified or overexpressed in multiple cancers (gastric, lung, renal, hepatocellular) HGF/c-Met activation promotes tumor cell proliferation, survival, invasion, and metastasis c-Met inhibitors are FDA-approved cancer drugs (cabozantinib, crizotinib, capmatinib) A compound that potentiates HGF/c-Met signaling raises theoretical concerns about promoting tumor growth or transformation with chronic use
Timing matters more than most people think
Kauzman A, Pavone M, Blanas N, Bradley G: Pigmented lesions of the oral cavity: review, differential diagnosis and case presentations
Acrodermatitis enteropathica reversibility of cerebral atrophy with zinc therapy
doi:10.1196/annals.1320.011